CCR4
ENSG00000183813
Target class
GPCR
Chromosome
3
Approved drugs
1
Clinical candidates (approved and in development)
1
- Approved drugs
- 1
- Clinical candidates (approved and in development)
- 1
- Chemical probe available
- No
- Target name
- CCR4
- Gene name
- C-C motif chemokine receptor 4
- Gene symbol
- CCR4
- Protein name
- C-C chemokine receptor type 4 (C-C CKR-4) (CC-CKR-4) (CCR-4) (CCR4) (K5-5) (CD antigen CD194)
- CC-CKR-4
- CMKBR4
- CKR4
- k5-5
- ChemR13
- CD194
- Gene biotype
- Protein coding
- Gene family
- CD molecules|C-C motif chemokine receptors
- Target class
- GPCR
- Target type
- Human gene
- Tissues expressed in
- 5
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 2.86
- Tissue specificity (Gini)
- 0.701
- Tissue specificity (tau)
- 0.896
- KEGG gene identifiers
- hsa:1233
- Protein interaction confidence
- 0.783368
- Protein interaction partners
- 19
- R-HSA-380108
- R-HSA-418594
- End position
- 32957120
- Start position
- 32951644
- Chromosome
- 3
- Strand
- Forward
- Cell membrane
- Multi-pass membrane protein.
- Plasma membrane
- Tissue specificity (tau)
- 0.895699
- Expression inequality (Gini)
- 0.700559
Expression in transcripts per million
- Lung
- 2.86
- Spleen
- 2.85
- Whole Blood
- 1.99
- Testis
- 1.97
- Small Intestine - Terminal Ileum
- 1.26
Expression in transcripts per million
- Lung2.86
- Spleen2.85
- Whole Blood1.99
- Testis1.97
- Small Intestine - Terminal Ileum1.26
- Skin - Not Sun Exposed (Suprapubic)0.52
- Cells - EBV-transformed lymphocytes0.5
- Adipose - Subcutaneous0.48
- Adipose - Visceral (Omentum)0.44
- Breast - Mammary Tissue0.35
- Fallopian Tube0.35
- Artery - Coronary0.35
- Vagina0.33
- Esophagus - Mucosa0.33
- Skin - Sun Exposed (Lower leg)0.31
- Colon - Transverse0.3
- Minor Salivary Gland0.3
- Thyroid0.28
- Artery - Aorta0.27
- Cervix - Endocervix0.26
- Kidney - Medulla0.26
- Prostate0.22
- Nerve - Tibial0.22
- Uterus0.17
- Stomach0.16
And 29 more, listed on the interactive page.
- GO:0006935
- GO:0006954
- GO:0006955
- GO:0007204
- GO:0060326
Cellular components
- GO:0005886
- GO:0004950
- GO:0005515
- GO:0016493
Related records
Trials (38)
- A Study of KW-0761 in Subjects With HTLV-1 Associated Myelopathy (HAM)
- A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1
- A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors
- A Study of VG712 in Patients With Mycosis Fungoides
- A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy
- AMG 761 in Adults With Asthma
- Anti-CCR4 Monoclonal Antibody (Mogamulizumab) and Total Skin Electron Beam Therapy (TSEB) in Patients With Stage IB-IIB Cutaneous T-Cell Lymphoma
- Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result Surveillance
- Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001
- Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma
- KHK2455 Alone and in Combination With Mogamulizumab in Subjects With Locally Advanced or Metastatic Solid Tumors
- KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)
- Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome
- Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides
- Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides
- Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma
- Mogamulizumab Q4week Dosing in Participants With R/R CTCL
- Multicenter, Randomized, Open-label, Parallel-group Study to Compare mLSG15 + KW-0761 to mLSG15
- Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas
- Phase I Study of KW-0761 in Relapsed Patients With CCR4-Positive ATL and PTCL
Drugs (1)
- Mogamulizumab C-C chemokine receptor type 4 cross-linking agent